Lumos Pharma, Inc. (NASDAQ:LUMO) Q4 2022 Earnings Conference Call March 1, 2023 4:30 PM ET

Company Participants

Lisa Miller - Senior Director, IR

Richard Hawkins - CEO & Chairman

Lori Lawley - CFO & Principal Accounting Officer

John McKew - Chief Scientific Officer & President

David Karpf - Chief Medical Officer

Conference Call Participants

Peter Rosenthal - Cantor

Catherine Novack - Jones Trading

Eun Yang - Jefferies

Ed White - H.C. Wainwright & Co.

Operator

Good afternoon, and welcome to Lumos Pharma's 2022 Financial Results Conference Call. [Operator Instructions].

We'll now turn the call over to Lisa Miller, Senior Director of Investor Relations. Ma'am, please go ahead.

Lisa Miller

Thank you, operator. Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under U.S. federal securities laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ is contained in our periodic reports filed with the SEC. The forward-looking statements made during this call speak only as of the date hereof, and the company undertakes no obligation to update or revise the forward-looking statements. Information presented on this call is contained in the press release we issued this afternoon, which may be accessed from the Investors page of the company's website and in our Form 10-K when filed.

Speaking on today's call will be Rick Hawkins, CEO and Chairman; and Lori Lawley, our CFO; John McKew, our President and Chief Scientific Officer; and David Karpf, our Chief Medical Officer, will join for questions-and-answer session after the call.

I will now turn the call over to Rick.

Richard Hawkins

Thank you, Lisa, and good afternoon, everyone. After the market closed today, we issued a press release announcing our 2022 full year financial results and clinical updates. On today's call, we'll keep our prepared remarks brief so we can maximize time available for Q&A. I'll touch on the highlights in the year and in recent weeks before turning it to Lori for a review of our financial results. Then John McKew and David Karpf will join us to answer your questions. So let's begin.

As we reported this afternoon, 2022 was a year of significant progress in advancing our oral therapeutic candidate, LUM-201 in Idiopathic Pediatric Growth Hormone Deficiency, or . We are pleased to announce patient enrollment has been completed in both our OraGrowtH210 and OraGrowtH212 trials. Given the obstacles that we faced with the impact from COVID, the Ukraine-Russia conflict, and a fire at our single OraGrowtH212 site, we are elated to be able to announce that the last subject in both trials have been enrolled, and we now expect to report primary outcome data on 82 subjects in the OraGrowtH 210 and 22 subjects in the PK/PD OraGrowtH212 trial. This accomplishment is a real tribute to the clinical team, and we expect to announce top line results from both trials in the fourth quarter of 2023.